B+
Bull case
25%
Probability
Target price
$340.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
SYK
StrykerDNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Q2 showed broad, volume-led organic growth, substantial adjusted margin expansion and double-digit adjusted EPS growth despite the cyber disruption. Sustained recovery and delivery near the high end of FY2026 guidance could support a rerating.
Posture
Defensive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-29 · AMC.
What can break
Execution risk against narrowed FY2026 organic-growth and adjusted-EPS guidance.
Momentum
37
Value
56
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $305.00 · Bull $340.00 · Bear $235.00Analysis 2026-09-11; returns require an exact persisted reference.
Earnings
32 · Non-qualifying
Next 2026-10-29 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-11 • Model: RankAlpha Sentiment Codex
Earnings Setup
As of 2026-10-26 • RankAlpha AI
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $364.48
Why
Momentum37 · Δ7d +28.4
Value56 · Δ7d -0.1
Sentiment46 · Δ7d -4.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Earnings surprise screen
32Non-qualifying2026-10-29 amc
Stryker reported 9% organic sales growth and narrowed its FY2026 outlook upward-contextually, while the stock strengthened over recent sessions; the checked sources did not establish positive current-quarter EPS revisions or a revenue upside revision, and the latest three-session price/volume confirmation is incomplete.
Screen as of 2026-10-26. Window 2026-10-26 to 2026-10-30.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-29 · AMC.
- • Pre-earnings setup: 32 / non-qualifying.
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Execution risk against narrowed FY2026 organic-growth and adjusted-EPS guidance.
- • Large August director share sales may weigh on sentiment, although they do not establish an operating deterioration. [#SEC-FORM4-2026-08-20]
- • Recent headlines attribute share weakness to supply-chain issues and slower peripheral-vascular and hip sales, but those claims lack packet-level primary-source confirmation.
Catalyst clock
2026-10-29 · AMC
Q2 recovery and narrowed FY2026 outlook
Lead driver: Value · See fundamentals
Momentum
37
8% active weight
Current posture
7d trendImproving
Δ7d
+28.4
Δ21d
+37.1
Value
56
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-1.4
Sentiment
46
45% active weight
Current posture
7d trendSoftening
Δ7d
-4.3
Δ21d
-20.2
Why this grade
Composite grade D. Momentum 36.8 / Value 55.9 / Sentiment 45.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-11. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$305.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$235.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$117.81B
Beta
0.88
Shares Out
383.57M
P/E (TTM)
45.8
P/S (TTM)
5.47
P/FCF (TTM)
47.55
Rev YoY
+9.4%
EPS YoY
+44.5%
Gross Margin
+63.0%
Op Margin
+24.3%
Net Debt
$12.26B
Current Ratio
2.16
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data